NASDAQ:ZLAB - Zai Lab Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $197.85
  • Forecasted Upside: 20.40 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$164.33
▲ +0.04 (0.02%)
1 month | 3 months | 12 months
Get New Zai Lab Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZLAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZLAB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$197.85
▲ +20.40% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Zai Lab in the last 3 months. The average price target is $197.85, with a high forecast of $250.00 and a low forecast of $111.00. The average price target represents a 20.40% upside from the last price of $164.33.
Buy
The current consensus among 5 polled investment analysts is to buy stock in Zai Lab. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/14/2021SVB LeerinkBoost Price TargetOutperform$183.00 ➝ $192.00Low
i
4/13/2021The Goldman Sachs GroupBoost Price TargetBuy$205.73 ➝ $211.23Medium
i
4/13/2021GuggenheimBoost Price Target$165.00 ➝ $250.00High
i
2/8/2021Jefferies Financial GroupBoost Price TargetBuy$130.00 ➝ $225.00Medium
i
2/3/2021SVB LeerinkBoost Price TargetOutperform$107.00 ➝ $189.00Low
i
11/16/2020JPMorgan Chase & Co.Boost Price Target$101.00 ➝ $111.00Low
i
11/3/2020JPMorgan Chase & Co.Boost Price TargetOverweight$65.00 ➝ $101.00Medium
i
9/10/2020SVB LeerinkBoost Price TargetOutperform$93.00 ➝ $95.00High
i
8/14/2020GuggenheimBoost Price TargetPositive ➝ Buy$105.00 ➝ $111.00Medium
i
Rating by Seamus Fernandez at Guggenheim
7/8/2020GuggenheimBoost Price TargetBuy$75.00 ➝ $105.00High
i
Rating by Seamus Fernandez at Guggenheim
7/7/2020SVB LeerinkBoost Price TargetOutperform$79.00 ➝ $93.00Low
i
4/27/2020The Goldman Sachs GroupInitiated CoverageBuyMedium
i
4/15/2020GuggenheimInitiated CoverageBuy$75.00Low
i
12/30/2019CitigroupBoost Price TargetBuy$65.00 ➝ $84.00Low
i
Rating by Yigal Nochomovitz at Citigroup Inc.
9/4/2019CitigroupSet Price TargetBuy$65.00Low
i
Rating by Yigal Nochomovitz at Citigroup Inc.
9/4/2019SVB LeerinkSet Price TargetBuy$48.00Low
i
Rating by Jonathan Chang at SVB Leerink LLC
9/4/2019China Renaissance SecuritiesInitiated CoverageBuyHigh
i
7/15/2019SVB LeerinkSet Price TargetBuy$47.00Low
i
Rating by Jonathan Chang at SVB Leerink LLC
7/12/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$43.00Medium
i
7/5/2019MacquarieInitiated CoverageOutperform ➝ Outperform$36.54Low
i
6/11/2019SVB LeerinkSet Price TargetBuy$46.00Medium
i
Rating by Jonathan Chang at SVB Leerink LLC
1/29/2019Credit Suisse GroupInitiated CoverageOutperform$34.70High
i
11/21/2018Jefferies Financial GroupInitiated CoverageBuy ➝ BuyLow
i
6/28/2018SVB LeerinkReiterated RatingOutperform$43.00Medium
i
Rating by J. Chang at SVB Leerink LLC
6/21/2018SVB LeerinkInitiated CoverageOutperform$43.00Medium
i
Rating by E. Darout at SVB Leerink LLC
3/23/2018SVB LeerinkReiterated RatingOutperformLow
i
Rating by E. Darout at SVB Leerink LLC
2/14/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$32.00High
i
10/16/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$42.00N/A
i
Rating by S. Fernandez at SVB Leerink LLC
10/16/2017CitigroupInitiated CoverageBuyN/A
i
10/16/2017JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$32.00N/A
i
(Data available from 4/19/2016 forward)
Zai Lab logo
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops, and commercializes therapeutics to treat oncology, autoimmune, and infectious diseases in China. The company offers ZEJULA for the treatment of breast cancer and non-small cell lung cancer (NSCLC); and Optune, a cancer therapy to treat glioblastoma multiforme. It also develops QINLOCK for the treatment of gastrointestinal stromal tumors; Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Bemarituzumab for the treatment of gastric and gastroesophageal junction cancer; and Omadacycline to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Efgartigimod to reduce disease-causing immunoglobulin G (IgG) antibodies; Retifanlimab to treat microsatellite instability high endometrial cancer; ZL-2309 for the treatment of metastatic pancreatic cancer, metastatic colorectal cancer, and other advanced solid tumors; ZL-1201 to treat solid tumors and hematological malignancies; ZL-1102 for the treatment of psoriasis; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited has license and collaboration agreements with the GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; and argenx BV. The company was incorporated in 2013 and is headquartered in Shanghai, China.
Read More

Today's Range

Now: $164.33
$162.02
$165.13

50 Day Range

MA: $137.71
$125.11
$164.83

52 Week Range

Now: $164.33
$58.59
$193.54

Volume

504,663 shs

Average Volume

444,979 shs

Market Capitalization

$14.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Zai Lab?

The following equities research analysts have issued reports on Zai Lab in the last twelve months: Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for ZLAB.

What is the current price target for Zai Lab?

5 Wall Street analysts have set twelve-month price targets for Zai Lab in the last year. Their average twelve-month price target is $197.85, suggesting a possible upside of 20.4%. Guggenheim has the highest price target set, predicting ZLAB will reach $250.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $111.00 for Zai Lab in the next year.
View the latest price targets for ZLAB.

What is the current consensus analyst rating for Zai Lab?

Zai Lab currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZLAB will outperform the market and that investors should add to their positions of Zai Lab.
View the latest ratings for ZLAB.

What other companies compete with Zai Lab?

How do I contact Zai Lab's investor relations team?

Zai Lab's physical mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company's listed phone number is 86-21-6163-2588 and its investor relations email address is [email protected] The official website for Zai Lab is www.zailaboratory.com.